|
Status |
Public on Jan 27, 2020 |
Title |
RNA-seq control (sgNT) and TLE3KO (sgTLE3) cells treated with 10 uM enzalutamide or vehicle |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by high throughput sequencing
|
Summary |
To investigate the transcriptional consequences of TLE3 loss in the presence/absence of AR inhibitor enzalutamide in prostate cancer cells, the transcriptomes of WT and TLE3KO cells treated with vehicle or enzalutamide (10 uM) were compared. .
|
|
|
Overall design |
WT and TLE3KO LNCaP cells treated with 10 uM enzalutamide or vehicle for 5 days (3 replicates)
|
|
|
Contributor(s) |
Palit S, Vis D, Lieftink C |
Citation(s) |
31855178 |
|
Submission date |
Apr 24, 2019 |
Last update date |
Jan 27, 2020 |
Contact name |
Sander Palit |
E-mail(s) |
s.palit@nki.nl
|
Organization name |
Netherlands Cancer Institute
|
Street address |
Plesmanlaan 121
|
City |
Amsterdam |
ZIP/Postal code |
1066 CX |
Country |
Netherlands |
|
|
Platforms (1) |
GPL16791 |
Illumina HiSeq 2500 (Homo sapiens) |
|
Samples (12)
|
|
Relations |
BioProject |
PRJNA534447 |
SRA |
SRP193707 |